Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein

Infectious Disorders - Drug Targets

Volumn 12, Issue 1, 2012, Pages 81-86

  Mediouni, Sonia ^a   Darque, Albert ^a   Baillat, Gilbert ^a   Ravaux, Isabelle ^a,b   Dhiver, Catherine ^b   Tissot Dupont, Hervé ^b   Mokhtari, Malika ^c   Moreau, Hervé ^c   Tamalet, Catherine ^d   Brunet, Corinne ^e   Paul, Pascale ^e   Dignat George, Françoise ^e   Stein, Andreas ^b   Brouqui, Philippe ^c   Spector, Stephen A ^f,g   Campbell, Grant R ^f   Loret, Erwann P ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c HÔPITAL NORD   (France)

^d TIMONE HOSPITAL   (France)

^e INSERM   (France)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Antibody; Antiretroviral therapy; B cell; HIV; Tat; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G ANTIBODY; TRANSACTIVATOR PROTEIN;

ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; LYMPHOCYTE COUNT; MALE; NONHUMAN; PROTEIN SECRETION; VIRUS LOAD; VIRUS PARTICLE;

EID: 84855837563     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152612798994939     Document Type: Article

References (32)

1. Autran, B.; Carcelain, G.; Li, T.S.; Blanc, C.; Mathez, D.; Tubiana, R.; Katlama, C.; Debre, P.; Leibowitch, J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science, 1997, 277(5322), 112-116.
2. Finzi, D.; Blankson, J.; Siliciano, J.D.; Margolick, J.B.; Chadwick, K.; Pierson, T.; Smith, K.; Lisziewicz, J.; Lori, F.; Flexner, C.; Quinn, T.C.; Chaisson, R.E.; Rosenberg, E.; Walker, B.; Gange, S.; Gallant, J.; Siliciano, R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med., 1999, 5(5), 512-517.
3. Ho, D.D.; Zhang, L. HIV-1 rebound after anti-retroviral therapy. Nat. Med., 2000, 6(7), 736-737.
4. Chun, T.W.; Nickle, D.C.; Justement, J.S.; Meyers, J.H.; Roby, G.; Hallahan, C.W.; Kottilil, S.; Moir, S.; Mican, J.M.; Mullins, J.I.; Ward, D.J.; Kovacs, J.A.; Mannon, P.J.; Fauci, A.S. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis., 2008, 197(5), 714-720.
5. Chun, T.W.; Finzi, D.; Margolick, J.; Chadwick, K.; Schwartz, D.; Siliciano, R.F. In vivo, fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med., 1995, 1(12), 1284-1290.
6. Emiliani, S.; Fischle, W.; Ott, M.; Van Lint, C.; Amella, C.A.; Verdin, E. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J. Virol., 1998, 72(2), 1666-1670.
7. Emiliani, S.; Van Lint, C.; Fischle, W.; Paras, P., Jr.; Ott, M.; Brady, J.; Verdin, E. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(13), 6377-6381.
8. Lassen, K.; Han, Y.; Zhou, Y.; Siliciano, J.; Siliciano, R.F. The multifactorial nature of HIV-1 latency. Trends Mol. Med., 2004, 10(11), 525-531.
9. Rayne, F.; Debaisieux, S.; Yezid, H.; Lin, Y.L.; Mettling, C.; Konate, K.; Chazal, N.; Arold, S.T.; Pugniere, M.; Sanchez, F.; Bonhoure, A.; Briant, L.; Loret, E.; Roy, C.; Beaumelle, B. Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J., 2010, 29(8), 1348-1362.
10. Campbell, G.R.; Loret, E.P. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology, 2009, 6, 50.
11. Green, M.; Loewenstein, P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell, 1988, 55(6), 1179-1188.
12. Chen, D.; Wang, M.; Zhou, S.; Zhou, Q. HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the proapoptotic Bcl-2 relative Bim. EMBO J., 2002, 21(24), 6801-6810.
13. de Mareuil, J.; Carre, M.; Barbier, P.; Campbell, G.R.; Lancelot, S.; Opi, S.; Esquieu, D.; Watkins, J.D.; Prevot, C.; Braguer, D.; Peyrot, V.; Loret, E.P. HIV-1 Tat protein enhances microtubule polymerization. Retrovirology, 2005, 2, 5.
14. Campbell, G.R.; Pasquier, E.; Watkins, J.; Bourgarel-Rey, V.; Peyrot, V.; Esquieu, D.; Barbier, P.; de Mareuil, J.; Braguer, D.; Kaleebu, P.; Yirrell, D.L.; Loret, E.P. The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J. Biol. Chem., 2004, 279(46), 48197-48204.
15. Lin, X.; Irwin, D.; Kanazawa, S.; Huang, L.; Romeo, J.; Yen, T.S.; Peterlin, B.M. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J. Virol., 2003, 77(15), 8227-8236.
16. Amarapal, P.; Tantivanich, S.; Balachandra, K.; Matsuo, K.; Pitisutithum, P.; Chongsa-nguan, M. The role of the Tat gene in the pathogenesis of HIV infection. Southeast Asian J. Trop. Med. Public Health, 2005, 36(2), 352-361.
17. Re, M.C.; Gibellini, D.; Furlini, G.; Vignoli, M.; Vitone, F.; Bon, I.; La Placa, M. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load. New Microbiol., 2001, 24(3), 207-215.
18. Butto, S.; Fiorelli, V.; Tripiciano, A.; Ruiz-Alvarez, M.J.; Scoglio, A.; Ensoli, F.; Ciccozzi, M.; Collacchi, B.; Sabbatucci, M.; Cafaro, A.; Guzman, C.A.; Borsetti, A.; Caputo, A.; Vardas, E.; Colvin, M.; Lukwiya, M.; Rezza, G.; Ensoli, B. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J. Infect. Dis., 2003, 188(8), 1171-1180.
19. Campbell, G.R.; Senkaali, D.; Watkins, J.; Esquieu, D.; Opi, S.; Yirrell, D.L.; Kaleebu, P.; Loret, E.P. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine, 2007, 25(50), 8441-8447.
20. Kashi, V.P.; Jacob, R.A.; Paul, S.; Nayak, K.; Satish, B.; Swaminathan, S.; Satish, K.S.; Ranga, U. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently. Vaccine, 2009, 27(48), 6739-6747.
21. Krone, W.J.; Debouck, C.; Epstein, L.G.; Heutink, P.; Meloen, R.; Goudsmit, J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J. Med. Virol., 1988, 26(3), 261-270.
22. Rezza, G.; Fiorelli, V.; Dorrucci, M.; Ciccozzi, M.; Tripiciano, A.; Scoglio, A.; Collacchi, B.; Ruiz-Alvarez, M.; Giannetto, C.; Caputo, A.; Tomasoni, L.; Castelli, F.; Sciandra, M.; Sinicco, A.; Ensoli, F.; Butto, S.; Ensoli, B. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J. Infect. Dis., 2005, 191(8), 1321-1324.
23. Richardson, M.W.; Mirchandani, J.; Duong, J.; Grimaldo, S.; Kocieda, V.; Hendel, H.; Khalili, K.; Zagury, J.F.; Rappaport, J. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed. Pharmacother., 2003, 57(1), 4-14.
24. Senkaali, D.; Kebba, A.; Shafer, L.A.; Campbell, G.R.; Loret, E.P.; Van Der Paal, L.; Grosskurth, H.; Yirrell, D.; Kaleebu, P. Tatspecific binding IgG and disease progression in HIV type 1-infected Ugandans. AIDS Res. Hum. Retroviruses, 2008, 24(4), 587-594.
25. Zagury, J.F.; Sill, A.; Blattner, W.; Lachgar, A.; Le Buanec, H.; Richardson, M.; Rappaport, J.; Hendel, H.; Bizzini, B.; Gringeri, A.; Carcagno, M.; Criscuolo, M.; Burny, A.; Gallo, R.C.; Zagury, D. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol., 1998, 1(4), 282-292.
26. Mediouni, S.; Baillat, G.; Darque, A.; Ravaux, I.; Loret, E. HIV-1 Infected Patients Have Antibodies Recognizing Folded Tat. Infect. Disord. Drug. Targets., 2010, 11(1), 57-63.
27. Barany, G.; Merrifield, R.B. Solid phase peptide synthesis. In The Peptide: Analysis, Synthesis, Biology, Gross, E.; Meinhofer, J., Eds.; Academic Press: New York, NY, 1980; Vol. 2, pp 1-284.
28. Péloponèse, J.M., Jr.; Collette, Y.; Grégoire, C.; Bailly, C.; Campèse, D.; Meurs, E.F.; Olive, D.; Loret, E.P. Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J. Biol. Chem., 1999, 274(17), 11473-11478.
29. Opi, S.; Péloponèse, J.M., Jr.; Esquieu, D.; Campbell, G.; de Mareuil, J.; Walburger, A.; Solomiac, M.; Gregoire, C.; Bouveret, E.; Yirrell, D.L.; Loret, E.P. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J. Biol. Chem., 2002, 277(39), 35915-35919.
30. Frey, A.; Di Canzio, J.; Zurakowski, D. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods, 1998, 221(1-2), 35-41.
31. Clerici, M.; Seminari, E.; Maggiolo, F.; Pan, A.; Migliorino, M.; Trabattoni, D.; Castelli, F.; Suter, F.; Fusi, M.L.; Minoli, L.; Carosi, G.; Maserati, R. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS, 2002, 16(13), 1767-1773.
32. Binley, J.M.; Klasse, P.J.; Cao, Y.; Jones, I.; Markowitz, M.; Ho, D.D.; Moore, J.P. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol., 1997, 71(4), 2799-2809.